World Equity Group Inc. Decreases Stock Position in Merck & Co., Inc. (NYSE:MRK)

World Equity Group Inc. reduced its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 9.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 11,040 shares of the company’s stock after selling 1,196 shares during the period. World Equity Group Inc.’s holdings in Merck & Co., Inc. were worth $1,098,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in MRK. Wellington Management Group LLP boosted its holdings in shares of Merck & Co., Inc. by 4.6% in the third quarter. Wellington Management Group LLP now owns 75,809,383 shares of the company’s stock worth $8,608,914,000 after acquiring an additional 3,327,404 shares during the period. Van ECK Associates Corp boosted its holdings in shares of Merck & Co., Inc. by 748.0% in the fourth quarter. Van ECK Associates Corp now owns 3,149,841 shares of the company’s stock worth $313,346,000 after acquiring an additional 2,778,388 shares during the period. Two Sigma Advisers LP boosted its stake in Merck & Co., Inc. by 157.9% during the third quarter. Two Sigma Advisers LP now owns 4,264,100 shares of the company’s stock valued at $484,231,000 after buying an additional 2,610,800 shares during the period. Caisse DE Depot ET Placement DU Quebec boosted its stake in Merck & Co., Inc. by 68.7% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 5,388,551 shares of the company’s stock valued at $611,924,000 after buying an additional 2,194,463 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Merck & Co., Inc. by 3.7% during the third quarter. Geode Capital Management LLC now owns 59,155,004 shares of the company’s stock valued at $6,696,060,000 after buying an additional 2,134,296 shares during the period. 76.07% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Inge G. Thulin purchased 2,833 shares of Merck & Co., Inc. stock in a transaction dated Thursday, February 6th. The stock was purchased at an average cost of $88.25 per share, for a total transaction of $250,012.25. Following the completion of the acquisition, the director now directly owns 2,933 shares of the company’s stock, valued at $258,837.25. The trade was a 2,833.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Cristal N. Downing sold 2,361 shares of Merck & Co., Inc. stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $88.76, for a total value of $209,562.36. Following the completion of the sale, the insider now owns 7,085 shares of the company’s stock, valued at $628,864.60. The trade was a 24.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Analyst Upgrades and Downgrades

MRK has been the subject of several research analyst reports. Leerink Partners dropped their price objective on Merck & Co., Inc. from $136.00 to $119.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. Truist Financial reissued a “hold” rating and set a $110.00 price objective (down previously from $130.00) on shares of Merck & Co., Inc. in a research note on Wednesday, January 8th. Hsbc Global Res raised Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 4th. Daiwa Capital Markets lowered Merck & Co., Inc. from a “buy” rating to a “neutral” rating in a research note on Monday, November 11th. Finally, Morgan Stanley reduced their price target on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nine have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus target price of $116.39.

Read Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $89.40 on Friday. The stock has a fifty day moving average of $95.46 and a 200 day moving average of $104.16. Merck & Co., Inc. has a 52 week low of $81.04 and a 52 week high of $134.63. The firm has a market capitalization of $226.14 billion, a price-to-earnings ratio of 13.28, a PEG ratio of 0.77 and a beta of 0.38. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by ($0.13). The firm had revenue of $15.62 billion for the quarter, compared to analysts’ expectations of $15.51 billion. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.03 EPS. As a group, research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. announced that its board has approved a stock repurchase program on Tuesday, January 28th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the company to purchase up to 4.1% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be issued a dividend of $0.81 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $3.24 annualized dividend and a dividend yield of 3.62%. Merck & Co., Inc.’s payout ratio is presently 48.14%.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.